Examining the Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for Alcohol Use Disorder Following Sexual Assault in College Women
The goal of this clinical trial is to determine whether women who engage in heavy drinking with a history of sexual assault (SA) victimization show heightened baseline reactivity to uncertain threat (U-threat), whether alcohol reduces this reactivity and related anxiety, and how these processes link to real-world drinking behavior. The main questions it aims to answer are:
- Test whether heavy drinking women with a history of SA display exaggerated baseline reactivity to U-threat.
- In the lab, test whether alcohol intoxication is associated with decreases in reactivity to U-threat and subjective anxiety, particularly in heavy drinking women with a history of SA.
- In the real-world, test associations between SA victimization, reactivity to U-threat, alcohol consumption, and anxiolytic relief.
Participants will:
- Complete a screening and orientation session
- Complete two experimental lab sessions that will include intravenous (IV) administration of either 80mg% alcohol or placebo (saline), order counterbalanced
- Complete daily ecological momentary assessments (EMA) surveys for 21 days
- Wear a transdermal alcohol wrist biosensor (BACTrack Skyn) for 21-days
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Première phase 1
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Stephanie Gorka
- Numéro de téléphone: 614-366-1027
- E-mail: stephanie.gorka@osumc.edu
Lieux d'étude
-
-
Ohio
-
Columbus, Ohio, États-Unis, 43210
- Recrutement
- Ohio State University
-
Contact:
- Stephanie Gorka
- Numéro de téléphone: 614-366-1027
- E-mail: stephanie.gorka@osumc.edu
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
General Inclusion Criteria for All Participants:
- Biological female
- 21-29 years old
- At least a high school education
- Fluency in English
- Heavy drinker as defined as 8 or more alcoholic drinks per week and at least two binge episodes (4 or more drinks for in a 2-hour period) in the past month
Additional Inclusion Criteria for Heavy Drinkers with History of Sexual Assault (HD+SA) Group:
- Self-reported experience of sexual assault victimization after age 14.
Additional Inclusion Criteria for Heavy Drinkers without History of Sexual Assault (HD-SA) Group:
- No exposure to lifetime DSM-5 Criterion A traumatic stressor. Participants will not be excluded for accidents, injuries, or witnessing community violence to ensure the sample is representative.
Exclusion Criteria for All Participants:
- Any serious medical problems (e.g., liver disease, cardiac abnormality, pancreatitis, diabetes, neurological problems, and gastrointestinal disorders)
- Body weight < 110 or > 210 lbs
- Current medical or psychiatric condition requiring medication for which alcohol consumption is contraindicated
- Substance use disorder other than mild and moderate alcohol use disorder
- Positive urine screen for drugs other than cannabis
- Currently seeking or past-12-month history of inpatient or intensive treatment for addictive behaviors
- Pregnancy, nursing, or planning to become pregnant in the next 3 months
- Report smoking more than 5 cigarettes (or electronic equivalent) per day
- Lifetime history of psychosis.
Additional Exclusion Criteria for HD+SA Group:
- Report a first onset SA within the past 30 days
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Autre: Heavy Drinking with a History of Sexual Assault Victimization (HD+SA)
Participants in this group will be required to be biological females between the ages of 21-29 who engage in heavy drinking with a history of sexual assault victimization after age 14. |
Participants receive placebo (saline) intravenously. Participants will receive 80 mg% intravenous alcohol. |
|
Autre: Heavy Drinking without a History of Sexual Assault Victimization (HD-SA)
Participants in this group will be required to be biological females between the ages of 21-29 who engage in heavy drinking either without a history of sexual assault victimization after age 14. |
Participants receive placebo (saline) intravenously. Participants will receive 80 mg% intravenous alcohol. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Startle eyeblink potentiation during the threat task
Délai: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
Startle eyeblink potentiation will be collected during the NPU threat task that is administered at all three lab sessions. Startle is a cross-species index of aversive reactivity. |
Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
|
Subjective affective response to alcohol in the lab
Délai: At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
Participants will complete the Profile of Mood States (POMS) throughout the placebo and alcohol administration protocols. The Profile of Mood States Anxiety subscale consists of 9 items, with each item rated from 0 (not at all) to 4 (extremely), resulting in a total score ranging from 0 to 36. Higher scores indicate greater subjective anxiety, while lower scores indicate less subjective anxiety. The Anxiety subscale will serve as the primary measure of subjective anxiety and will be compared between the placebo and alcohol sessions. |
At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
|
Subjective effects of alcohol in the lab
Délai: At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
Participants will rate the degree to which they 'feel', 'like', and 'want more' of the infused substance on a visual analogue scale ranging from 0 ('not at all') to 100 ('extremely'). The 'like' and 'want more' scales will serve as the primary measures of drug liking and drug wanting, respectively. |
At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
|
Ecological momentary assessment (EMA) of affective response to alcohol in the real world
Délai: Assessed daily for 21-days
|
Up to five times per day, participants will complete ecological momentary assessments (EMA) of their current anxiety, distress, and other mood states. Participants will rate each emotion on a 0-5 scale, where 0 = not at all and 5 = extremely. Affect will be assessed during periods of sobriety and intoxication. |
Assessed daily for 21-days
|
|
Transdermal alcohol concentration (TAC)
Délai: Assessed daily for 21-days
|
Participants' TAC will provide an objective estimate of alcohol consumption. |
Assessed daily for 21-days
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 2024H0264
- 1R01AA032115-01A1 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified data, including startle eyeblink and behavior, from this project will be submitted to the The National Institute on Alcohol Abuse and Alcoholism Data Archive (NIAAADA) at the subject level along with appropriate supporting documentation to enable efficient use of the data by the research community. We will follow instructions as discussed in the NDA Data Sharing Terms and Conditions.
Délai de partage IPD
The data will be submitted biannually.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .